A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice

Journal of Experimental Medicine

Volumn 211, Issue 6, 2014, Pages 1049-1062

  Ahn, Hyung Jin ^a   Fraser Glickman, J ^a   Poon, Ka Lai ^a   Zamolodchikov, Daria ^a   Jno Charles, Odella C ^a   Norris, Erin H ^a   Strickland, Sidney ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BLOOD CLOTTING INHIBITOR; FIBRINOGEN; RU 505; SULINDAC; SULINDAC SULFIDE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CLOTTING; BRAIN BLOOD FLOW; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SCREENING; FEMALE; FIBRIN CLOT; FIBRIN DEPOSITION; FIBRINOLYSIS; FLUORESCENCE POLARIZATION; GLIOSIS; HIGH THROUGHPUT SCREENING; LONG TERM CARE; MALE; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE DRUG DOSE; SPATIAL LEARNING; SPATIAL MEMORY; SURFACE PLASMON RESONANCE; THROMBOSIS; TURBIDITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FIBRINOGEN; HUMANS; MAZE LEARNING; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PROTEIN BINDING; PYRAZOLES; PYRIMIDINES; SMALL MOLECULE LIBRARIES; THROMBOSIS; TIME-LAPSE IMAGING;

EID: 84901801735     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20131751     Document Type: Article

References (48)

1. Adams, R.A., J. Bauer, M.J. Flick, S.L. Sikorski, T. Nuriel, H. Lassmann, J.L. Degen, and K. Akassoglou. 2007. The fibrin-derived gamma 377-395. peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 204:571-582. http://dx.doi.org/10.1084/jem.20061931.
2. Ahn, H.J., D. Zamolodchikov, M. Cortes-Canteli, E.H. Norris, J.F. Glickman, and S. Strickland. 2010. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. USA. 107:21812-21817. http://dx.doi.org/10.1073/pnas.1010373107.
3. Bayer, T.A., R. Buslei, L. Havas, and P. Falkai. 1999. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271:126-128. http://dx.doi.org/10.1016/S0304-3940(99)00545-5.
4. Brundel, M., J. de Bresser, J.J. van Dillen, L.J. Kappelle, and G.J. Biessels. 2012. Cerebral microinfarcts: a systematic review of neuropathological studies. J. Cereb. Blood Flow Metab. 32:425-436. http://dx.doi.org/10.1038/jcbfm.2011.200.
5. Chen, Y.W., M.E. Gurol, J. Rosand, A. Viswanathan, S.M. Rakich, T.R. Groover, S.M. Greenberg, and E.E. Smith. 2006. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology. 67:83-87. http://dx.doi.org/10.1212/01.wnl.0000223613.57229.24.
6. Chishti, M.A., D.S. Yang, C. Janus, A.L. Phinney, P. Horne, J. Pearson, R. Strome, N. Zuker, J. Loukides, J. French, et al. 2001. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276:21562-21570. http://dx.doi.org/10.1074/jbc.M100710200.
7. Cleary, J.P., D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, and K.H. Ashe. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84. http://dx.doi.org/10.1038/nn1372.
8. Cortes-Canteli, M., J. Paul, E.H. Norris, R. Bronstein, H.J. Ahn, D. Zamolodchikov, S. Bhuvanendran, K.M. Fenz, and S. Strickland. 2010. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron. 66:695-709. http://dx.doi.org/10.1016/j.neuron.2010.05.014.
9. Craig-Schapiro, R., M. Kuhn, C. Xiong, E.H. Pickering, J. Liu, T.P. Misko, R.J. Perrin, K.R. Bales, H. Soares, A.M. Fagan, and D.M. Holtzman. 2011. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS ONE. 6:e18850. http://dx.doi.org/10.1371/journal.pone.0018850.
10. Davalos, D., and K. Akassoglou. 2012. Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 34:43-62. http://dx.doi.org/ 10.1007/s00281-011-0290-8.
11. de la Torre, J.C. 2004. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3:184-190. http://dx.doi.org/10.1016/S1474-4422(04)00683-0.
12. Dhawan, G., and C.K. Combs. 2012. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. J. Neuroinflammation. 9:117. http://dx.doi.org/10.1186/1742-2094-9-117.
13. Gilman, S., M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette, and J.M. Orgogozo; AN1792(QS-21)-201 Study Team. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 64:1553-1562. http://dx.doi.org/10.1212/01.WNL.0000159740.16984.3C.
14. Jonsson, T., J.K. Atwal, S. Steinberg, J. Snaedal, P.V. Jonsson, S. Bjornsson, H. Stefansson, P. Sulem, D. Gudbjartsson, J. Maloney, et al. 2012. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 488:96-99. http://dx.doi.org/10.1038/nature11283.
15. Klohs, J., C. Baltes, F. Princz-Kranz, D. Ratering, R.M. Nitsch, I. Knuesel, and M. Rudin. 2012. Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAβ mice. J. Neurosci. 32:1705-1713. http://dx.doi.org/ 10.1523/JNEUROSCI.5626-11.2012.
16. Lipinski, C.A., F. Lombardo, B.W. Dominy, and P.J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26. http://dx.doi.org/10.1016/S0169-409X(00)00129-0.
17. Mangialasche, F., A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto. 2010. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9:702-716. http://dx.doi.org/10.1016/S1474-4422(10)70119-8.
18. McGowan, E., F. Pickford, J. Kim, L. Onstead, J. Eriksen, C. Yu, L. Skipper, M.P. Murphy, J. Beard, P. Das, et al. 2005. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 47:191-199. http://dx.doi.org/10.1016/j.neuron.2005.06.030.
19. Mortimer, J.A. 2012. The Nun Study: risk factors for pathology and clinicalpathologic correlations. Curr. Alzheimer Res. 9:621-627. http://dx.doi.org/10.2174/156720512801322546.
20. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study; Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). 2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 357:169-175. http://dx.doi.org/ 10.1016/S0140-6736(00)03589-3.
21. Oakley, H., S.L. Cole, S. Logan, E. Maus, P. Shao, J. Craft, A. Guillozet-Bongaarts, M. Ohno, J. Disterhoft, L. Van Eldik, et al. 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129-10140. http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006.
22. Okamoto, Y., M. Ihara, H. Tomimoto, W. Taylor Kimberly, and S.M. Greenberg. 2010. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology. 74:93, author reply :93. http:// dx.doi.org/10.1212/WNL.0b013e3181c77627.
23. Park, L., J. Zhou, P. Zhou, R. Pistick, S. El Jamal, L. Younkin, J. Pierce, A. Arreguin, J. Anrather, S.G. Younkin, et al. 2013. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. USA. 110:3089-3094. http://dx.doi.org/10.1073/pnas.1300021110.
24. Paul, J., S. Strickland, and J.P. Melchor. 2007. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 204:1999-2008. http://dx.doi.org/10.1084/jem.20070304.
25. Pfeifer, L.A., L.R. White, G.W. Ross, H. Petrovitch, and L.J. Launer. 2002. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 58:1629-1634. http://dx.doi.org/10.1212/WNL.58.11.1629.
26. Ratner, J., G. Rosenberg, V.A. Kral, and F. Engelsmann. 1972. Anticoagulant therapy for senile dementia. J. Am. Geriatr. Soc. 20:556-559.
27. Richter, L., L.M. Munter, J. Ness, P.W. Hildebrand, M. Dasari, S. Unterreitmeier, B. Bulic, M. Beyermann, R. Gust, B. Reif, et al. 2010. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc. Natl. Acad. Sci. USA. 107:14597-14602. http://dx.doi.org/10.1073/pnas.1003026107.
28. Roher, A.E., J.D. Lowenson, S. Clarke, A.S. Woods, R.J. Cotter, E. Gowing, and M.J. Ball. 1993. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:10836-10840. http://dx.doi.org/10.1073/pnas.90.22.10836.
29. Ryu, J.K., and J.G. McLarnon. 2009. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell. Mol. Med. 13(9A):2911-2925. http://dx.doi.org/10.1111/ j.1582-4934.2008.00434.x.
30. Shinkai, Y., M. Yoshimura, Y. Ito, A. Odaka, N. Suzuki, K. Yanagisawa, and Y. Ihara. 1995. Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra-and intracranial blood vessels. Ann. Neurol. 38:421-428. http://dx.doi.org/10.1002/ana.410380312.
31. Smith, E.E., and S.M. Greenberg. 2009. Beta-amyloid, blood vessels, and brain function. Stroke. 40:2601-2606. http://dx.doi.org/10.1161/STROKEAHA.108.536839.
32. Snowdon, D.A., L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner, and W.R. Markesbery. 1997. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 277:813-817. http:// dx.doi.org/10.1001/jama.1997.03540340047031.
33. Stine, W.B., L. Jungbauer, C. Yu, and M.J. LaDu. 2011. Preparing synthetic Aβ in different aggregation states. Methods Mol. Biol. 670:13-32. http:// dx.doi.org/10.1007/978-1-60761-744-0_2.
34. Suzuki, N., T. Iwatsubo, A. Odaka, Y. Ishibashi, C. Kitada, and Y. Ihara. 1994. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am. J. Pathol. 145:452-460.
35. Tanzi, R.E., and L. Bertram. 2005. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 120:545-555. http:// dx.doi.org/10.1016/j.cell.2005.02.008.
36. Thal, D.R., W.S. Griffin, R.A. de Vos, and E. Ghebremedhin. 2008. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 115:599-609. http://dx.doi.org/10.1007/s00401-008-0366-2.
37. Thambisetty, M., A. Simmons, A. Hye, J. Campbell, E. Westman, Y. Zhang, L.O. Wahlund, A. Kinsey, M. Causevic, R. Killick, et al. AddNeuroMed Consortium. 2011. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS ONE. 6:e28527. http://dx.doi.org/ 10.1371/journal.pone.0028527.
38. Timmer, N.M., L. van Dijk, C.E. van der Zee, A. Kiliaan, R.M. de Waal, and M.M. Verbeek. 2010. Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/ PS1dE9 mice with differential effects on brain Aβ levels. Neurobiol. Dis. 40:340-347. http://dx.doi.org/10.1016/j.nbd.2010.06.008.
39. Vafadar-Isfahani, B., G. Ball, C. Coveney, C. Lemetre, D. Boocock, L. Minthon, O. Hansson, A.K. Miles, S.M. Janciauskiene, D. Warden, et al. 2012. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. J. Alzheimers Dis. 28:625-636.
40. Van Dorpe, J., L. Smeijers, I. Dewachter, D. Nuyens, K. Spittaels, C. Van Den Haute, M. Mercken, D. Moechars, I. Laenen, C. Kuiperi, et al. 2000. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 157:1283-1298. http://dx.doi.org/10.1016/S0002-9440(10)64644-5.
41. van Oijen, M., J.C. Witteman, A. Hofman, P.J. Koudstaal, and M.M. Breteler. 2005. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke. 36:2637-2641. http:// dx.doi.org/10.1161/01.STR.0000189721.31432.26.
42. Viswanathan, A., W.A. Rocca, and C. Tzourio. 2009. Vascular risk factors and dementia: how to move forward? Neurology. 72:368-374. http:// dx.doi.org/10.1212/01.wnl.0000341271.90478.8e.
43. Vom Berg, J., S. Prokop, K.R. Miller, J. Obst, R.E. Kälin, I. Lopategui-Cabezas, A. Wegner, F. Mair, C.G. Schipke, O. Peters, et al. 2012. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med. 18:1812-1819. http://dx.doi.org/10.1038/nm.2965.
44. Walker, J.M., S.W. Fowler, D.K. Miller, A.Y. Sun, G.A. Weisman, W.G. Wood, G.Y. Sun, A. Simonyi, and T.R. Schachtman. 2011. Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease. Behav. Brain Res. 222:169-175. http://dx.doi.org/10.1016/j.bbr.2011.03.049.
45. Walsh, A.C., B.H. Walsh, and C. Melaney. 1978. Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen. J. Am. Geriatr. Soc. 26:467-470.
46. Xu, G., H. Zhang, S. Zhang, X. Fan, and X. Liu. 2008. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int. J. Clin. Pract. 62:1070-1075. http:// dx.doi.org/10.1111/j.1742-1241.2007.01268.x.
47. Yoshiike, Y., D.H. Chui, T. Akagi, N. Tanaka, and A. Takashima. 2003. Specific compositions of amyloid-beta peptides as the determinant of toxic betaaggregation. J. Biol. Chem. 278:23648-23655. http://dx.doi.org/10.1074/ jbc.M212785200.
48. Zamolodchikov, D., and S. Strickland. 2012. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood. 119:3342-3351. http://dx.doi.org/10.1182/blood-2011-11-389668.